A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs GB 001 (Primary)
- Indications Allergic asthma; Asthma
- Focus Therapeutic Use
- Acronyms LEDA
- Sponsors Gossamer Bio
- 12 Nov 2019 According to a Gossamer Bio media release, results of post hoc analysis from the study were presented at the European Respiratory Society (ERS) International Congress 2019.
- 08 Aug 2019 According to a Gossamer Bio media release, full results from the study are expected in the second half of 2020.
- 14 May 2019 According to a Gossamer Bio media release, results from an interim analysis expected in the first half of 2020.